Virulence-associated enzymes of Cryptococcus neoformans

Eukaryotic Cell

Volumn 14, Issue 12, 2015, Pages 1173-1185

  Almeida, Fausto ^a,b   Wolf, Julie M ^a   Casadevall, Arturo ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANIN; POLYSACCHARIDE;

ANIMAL; ANTIFUNGAL RESISTANCE; BIOSYNTHESIS; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; ENZYMOLOGY; HUMAN; METABOLISM; PATHOGENICITY; VIRULENCE;

ANIMALS; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG RESISTANCE, FUNGAL; HUMANS; MELANINS; POLYSACCHARIDES; VIRULENCE;

EID: 84949033948     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.00103-15     Document Type: Review

References (202)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TA. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
2. Heitman J, Kozel TR, Kwon-Chung J, Perfect JR, Casadevall A. 2011. Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.
3. Nielsen K, De Obaldia AL, Heitman J. 2007. Cryptococcus neoformans mates on pigeon guano: implications for the realized ecological niche and globalization. Eukaryot Cell 6:949-959. http://dx.doi.org/10.1128/EC.00097-07.
4. Mitchell TG, Perfect JR. 1995. Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8:515-548.
5. Williamson PR. 1997. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Front Biosci 2:e99-e107.
6. Casadevall A, Rosas AL, Nosanchuk JD. 2000. Melanin and virulence in Cryptococcus neoformans. Curr Opin Microbiol 3:354-358. http://dx.doi.org/10.1016/S1369-5274(00)00103-X.
7. Casadevall A, Perfect JR. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
8. Kronstad J, Saikia S, Nielson ED, Kretschmer M, Jung W, Hu G, Geddes JM, Griffiths EJ, Choi J, Cadieux B, Caza M, Attarian R. 2012. Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence. Eukaryot Cell 11:109-118. http://dx.doi.org/10.1128/EC.05273-11.
9. Cherniak R, Reiss E, Turner SH. 1982. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr Res 103:239-250. http://dx.doi.org/10.1016/S0008-6215(00)80686-2.
10. Cherniak R, Sundstrom JB. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 62:1507-1512.
11. Bose I, Reese AJ, Ory JJ, Janbon G, Doering TL. 2003. A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell 2:655-663. http://dx.doi.org/10.1128/EC.2.4.655-663.2003.
12. Kozel TR, Levitz SM, Dromer F, Gates MA, Thorkildson P, Janbon G. 2003. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsularOacetylation or xylosyl side chains. Infect Immun 71:2868-2875. http://dx.doi.org/10.1128/IAI.71.5.2868-2875.2003.
13. Heiss C, Klutts JS, Wang Z, Doering TL, Azadi P. 2009. The structure of Cryptococcus neoformans galactoxylomannan contains beta-Dglucuronic acid. Carbohydr Res 344:915-920. http://dx.doi.org/10.1016/j.carres.2009.03.003.
14. Jesus MD, Nicola AM, Chow SK, Lee IR, Nong S, Specht CA, Levitz SM, Casadevall A. 2010. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence 1:500-508. http://dx.doi.org/10.4161/viru.1.6.13451.
15. Rodrigues ML, Nimrichter L. 2012. In good company: association between fungal glycans generates molecular complexes with unique functions. Frontiers Microbiol 3:249.
16. O’Meara TR, Alspaugh JA. 2012. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev 25:387-408. http://dx.doi.org/10.1128/CMR.00001-12.
17. Chang YC, Kwon-Chung KJ. 1994. Complementation of a capsuledeficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14:4912-4919. http://dx.doi.org/10.1128/MCB.14.7.4912.
18. Rodrigues ML, Alviano CS, Travassos LR. 1999. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infect 1:293-301. http://dx.doi.org/10.1016/S1286-4579(99)80025-2.
19. Kozel TR, Pfrommer GS, Guerlain AS, Highison BA, Highison GJ. 1988. Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis 10(Suppl 2):S436-S439. http://dx.doi.org/10.1093/cid/10.Supplement_2.S436.
20. Pericolini E, Cenci E, Monari C, De Jesus M, Bistoni F, Casadevall A, Vecchiarelli A. 2006. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol 8:267-275. http://dx.doi.org/10.1111/j.1462-5822.2005.00619.x.
21. Vecchiarelli A, Monari C. 2012. Capsular material of Cryptococcus neoformans: virulence and much more. Mycopathologia 173:375-386. http://dx.doi.org/10.1007/s11046-011-9513-8.
22. Trevijano-Contador N, Herrero-Fernandez I, Garcia-Barbazan I, Scorzoni L, Rueda C, Rossi SA, Garcia-Rodas R, Zaragoza O. 2015. Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence 6:66-74. http://dx.doi.org/10.4161/21505594.2014.986412.
23. Alvarez M, Burn T, Luo Y, Pirofski LA, Casadevall A. 2009. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol 9:51. http://dx.doi.org/10.1186/1471-2180-9-51.
24. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. 2009. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 68:133-216. http://dx.doi.org/10.1016/S0065-2164(09)01204-0.
25. Frases S, Pontes B, Nimrichter L, Viana NB, Rodrigues ML, Casadevall A. 2009. Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A 106:1228-1233. http://dx.doi.org/10.1073/pnas.0808995106.
26. McFadden DC, De Jesus M, Casadevall A. 2006. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem 281:1868-1875. http://dx.doi.org/10.1074/jbc.M509465200.
27. Cordero RJ, Frases S, Guimaraes AJ, Rivera J, Casadevall A. 2011. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol 79:1101-1117. http://dx.doi.org/10.1111/j.1365-2958.2010.07511.x.
28. White CW, Cherniak R, Jacobson ES. 1990. Side group addition by xylosyltransferase and glucuronyltransferase in biosynthesis of capsular polysaccharide in Cryptococcus neoformans. J Med Vet Mycol 28:289-301. http://dx.doi.org/10.1080/02681219080000381.
29. Castle SA, Owuor EA, Thompson SH, Garnsey MR, Klutts JS, Doering TL, Levery SB. 2008. β1,2-Xylosyltransferase Cxt1p is solely responsible for xylose incorporation into Cryptococcus neoformans glycosphingolipids. Eukaryot Cell 7:1611-1615. http://dx.doi.org/10.1128/EC.00458-07.
30. Klutts JS, Doering TL. 2008. Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. J Biol Chem 283:14327-14334. http://dx.doi.org/10.1074/jbc.M708927200.
31. Klutts JS, Levery SB, Doering TL. 2007. A beta-1,2-xylosyltransferase from Cryptococcus neoformans defines a new family of glycosyltransferases. J Biol Chem 282:17890-17899. http://dx.doi.org/10.1074/jbc.M701941200.
32. Chang YC, Kwon-Chung KJ. 1999. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol 181:5636-5643.
33. Chang YC, Penoyer LA, KwonChung KJ. 1996. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 64:1977-1983.
34. Chang YC, Kwon-Chung KJ. 1998. Isolation of the third capsuleassociated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun 66:2230-2236.
35. Jacobson ES, Tingler MJ. 1994. Strains of Cryptococcus neoformans with defined capsular phenotypes. J Med Vet Mycol 32:401-404. http://dx.doi.org/10.1080/02681219480000531.
36. Tefsen B, Grijpstra J, Ordonez S, Lammers M, van Die I, de Cock H. 2014. Deletion of the CAP10 gene of Cryptococcus neoformans results in a pleiotropic phenotype with changes in expression of virulence factors. Res Microbiol 165:399-410. http://dx.doi.org/10.1016/j.resmic.2014.04.001.
37. Park YD, Shin S, Panepinto J, Ramos J, Qiu J, Frases S, Albuquerque P, Cordero RJ, Zhang N, Himmelreich U, Beenhouwer D, Bennett JE, Casadevall A, Williamson PR. 2014. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule. PLoS Pathog 10:e1004037. http://dx.doi.org/10.1371/journal.ppat.1004037.
38. Doering TL. 1999. A unique alpha-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans. J Bacteriol 181:5482-5488.
39. Sommer U, Liu H, Doering TL. 2003. An alpha-1,3-mannosyltransferase of Cryptococcus neoformans. J Biol Chem 278:47724-47730. http://dx.doi.org/10.1074/jbc.M307223200.
40. Bennett JE, Kwonchung KJ, Howard DH. 1977. Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol 105: 582-586.
41. Rosas AL, Casadevall A. 1997. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett 153: 265-272. http://dx.doi.org/10.1016/S0378-1097(97)00239-5.
42. Khajo A, Bryan RA, Friedman M, Burger RM, Levitsky Y, Casadevall A, Magliozzo RS, Dadachova E. 2011. Protection of melanized Cryptococcus neoformans from lethal dose gamma irradiation involves changes in melanin’s chemical structure and paramagnetism. PLoS One 6:e25092. http://dx.doi.org/10.1371/journal.pone.0025092.
43. Shaw CE, Kapica L. 1972. Production of diagnostic pigment by phenoloxidase activity of Cryptococcus neoformans. Appl Microbiol 24:824-830.
44. Wang Y, Aisen P, Casadevall A. 1996. Melanin, melanin “ghosts,” and melanin composition in Cryptococcus neoformans. Infect Immun 64: 2420-2424.
45. Williamson PR. 1994. Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans—identification as a laccase. J Bacteriol 176:656-664.
46. Ikeda R, Shinoda T, Morita T, Jacobson ES. 1993. Characterization of a phenol oxidase from Cryptococcus neoformans var. neoformans. Microbiol Immunol 37:759-764. http://dx.doi.org/10.1111/j.1348-0421.1993.tb01702.x.
47. Chaskes S, Tyndall RL. 1975. Pigment production by Cryptococcus neoformans from para- and ortho-diphenols: effect of the nitrogen source. J Clin Microbiol 1:509-514.
48. Edberg SC, Chaskes SJ, Alture-Werber E, Singer JM. 1980. Esculinbased medium for isolation and identification of Cryptococcus neoformans. J Clin Microbiol 12:332-335.
49. Kwon-Chung KJ, Tom WK, Costa JL. 1983. Utilization of indole compounds by Cryptococcus neoformans to produce a melanin-like pigment. J Clin Microbiol 18:1419-1421.
50. Polacheck I, Hearing VJ, Kwon-Chung KJ. 1982. Biochemical studies of phenoloxidase and utilization of catecholamines in Cryptococcus neoformans. J Bacteriol 150:1212-1220.
51. Polacheck I, Platt Y, Aronovitch J. 1990. Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 58:2919-2922.
52. Strachan AA, Yu RJ, Blank F. 1971. Pigment production of Cryptococcus neoformans grown with extracts of Guizotia abyssinica. Appl Microbiol 22:478-479.
53. Wang HS, Zeimis RT, Roberts GD. 1977. Evaluation of a caffeic acidferric citrate test for rapid identification of Cryptococcus neoformans. J Clin Microbiol 6:445-449.
54. Jacobson ES, Compton GM. 1996. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans. J Med Vet Mycol 34:289-291. http://dx.doi.org/10.1080/02681219680000491.
55. Missall TA, Moran JM, Corbett JA, Lodge JK. 2005. Distinct stress responses of two functional laccases in Cryptococcus neoformans are revealed in the absence of the thiol-specific antioxidant Tsa1. Eukaryot Cell 4:202-208. http://dx.doi.org/10.1128/EC.4.1.202-208.2005.
56. Pukkila-Worley R, Gerrald QD, Kraus PR, Boily MJ, Davis MJ, Giles SS, Cox GM, Heitman J, Alspaugh JA. 2005. Transcriptional network of multiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryot Cell 4:190-201. http://dx.doi.org/10.1128/EC.4.1.190-201.2005.
57. Zhu X, Williamson PR. 2004. Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res 5:1-10. http://dx.doi.org/10.1016/j.femsyr.2004.04.004.
58. Zhu XD, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR. 2001. Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun 69:5589-5596. http://dx.doi.org/10.1128/IAI.69.9.5589-5596.2001.
59. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR. 1996. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 184:377-386. http://dx.doi.org/10.1084/jem.184.2.377.
60. Wang Y, Casadevall A. 1994. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun 62:3004-3007.
61. Wang Y, Aisen P, Casadevall A. 1995. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 63:3131-3136.
62. Jacobson ES, Tinnell SB. 1993. Antioxidant function of fungal melanin. J Bacteriol 175:7102-7104.
63. van Duin D, Casadevall A, Nosanchuk JD. 2002. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 46:3394-3400. http://dx.doi.org/10.1128/AAC.46.11.3394-3400.2002.
64. Ikeda R, Sugita T, Jacobson ES, Shinoda T. 2003. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol 47:271-277. http://dx.doi.org/10.1111/j.1348-0421.2003.tb03395.x.
65. Wang YL, Casadevall A. 1994. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother 38:2648-2650. http://dx.doi.org/10.1128/AAC.38.11.2648.
66. Almeida FB, Cerqueira FM, Silva Rdo N, Ulhoa CJ, Lima AL. 2007. Mycoparasitism studies of Trichoderma harzianum strains against Rhizoctonia solani: evaluation of coiling and hydrolytic enzyme production. Biotechnol Lett 29:1189-1193. http://dx.doi.org/10.1007/s10529-007-9372-z.
67. Dos Reis Almeida FB, de Oliveira LL, de Sousa MV, Barreira MCR, Hanna ES. 2010. Paracoccin from Paracoccidioides brasiliensis; purification through affinity with chitin and identification of N-acetyl-beta-Dglucosaminidase activity. Yeast 27:67-76.
68. Dos Reis Almeida FB, Carvalho FC, Mariano VS, Alegre ACP, Silva RD, Hanna ES, Roque-Barreira MC. 2011. Influence of N-glycosylation on the morphogenesis and growth of Paracoccidioides brasiliensis and on the biological activities of yeast proteins. PLoS One 6:e29216. http://dx.doi.org/10.1371/journal.pone.0029216.
69. Dos Reis Almeida FB, Pigosso LL, de Lima Damasio AR, Monteiro VN, de Almeida Soares CM, Silva RN, Roque-Barreira MC. 2014. Alpha-(1,4)-Amylase, but not alpha- and beta-(1,3)-glucanases, may be responsible for the impaired growth and morphogenesis of Paracoccidioides brasiliensis induced by N-glycosylation inhibition. Yeast 31:1-11. http://dx.doi.org/10.1002/yea.2983.
70. Partridge BM, Winner HI. 1965. Cryptococcus neoformans in bird droppings in London. Lancet i:1060-1061.
71. Walter JE, Yee RB. 1968. Factors that determine the growth of Cryptococcus neoformans in avian excreta. Am J Epidemiol 88:445-450.
72. Kwon-Chung KJ, Wickes BL, Booth JL, Vishniac HS, Bennett JE. 1987. Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans. Infect Immun 55:1751-1754.
73. Vogel RA. 1969. Primary isolation medium for Cryptococcus neoformans. Appl Microbiol 18:1100.
74. Zimmer BL, Roberts GD. 1979. Rapid selective urease test for presumptive identification of Cryptococcus neoformans. J Clin Microbiol 10:380-381.
75. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68: 443-448. http://dx.doi.org/10.1128/IAI.68.2.443-448.2000.
76. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB. 2004. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 164:1761-1771. http://dx.doi.org/10.1016/S0002-9440(10)63734-0.
77. Bava AJ, Negroni R, Bianchi M. 1993. Cryptococcosis produced by a urease negative strain of Cryptococcus neoformans. J Med Vet Mycol 31: 87-89. http://dx.doi.org/10.1080/02681219380000091.
78. Ruane PJ, Walker LJ, George WL. 1988. Disseminated infection caused by urease-negative Cryptococcus neoformans. J Clin Microbiol 26:2224-2225.
79. Cazin J, Jr, Kozel TR, Lupan DM, Burt WR. 1969. Extracellular deoxyribonuclease production by yeasts. J Bacteriol 100:760-762.
80. Rocha JD, Nascimento MT, Decote-Ricardo D, Corte-Real S, Morrot A, Heise N, Nunes MP, Previato JO, Mendonca-Previato L, DosReis GA, Saraiva EM, Freire-de-Lima CG. 2015. Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils. Sci Rep 5:8008. http://dx.doi.org/10.1038/srep08008.
81. Sanchez M, Colom F. 2010. Extracellular DNase activity of Cryptococcus neoformans and Cryptococcus gattii. Rev Iberoam Micol 27:10-13. http://dx.doi.org/10.1016/j.riam.2009.11.004.
82. Fridovich I. 1995. Superoxide radical and superoxide dismutases. Annu Rev Biochem 64:97-112. http://dx.doi.org/10.1146/annurev.bi.64.070195.000525.
83. Hamilton AJ, Holdom MD. 1997. Biochemical comparison of the Cu,Zn superoxide dismutases of Cryptococcus neoformans var. neoformans and Cryptococcus neoformans var. gattii. Infect Immun 65:488-494.
84. Tesfa-Selase F, Hay RJ. 1995. Superoxide dismutase of Cryptococcus neoformans: purification and characterization. J Med Vet Mycol 33:253-259. http://dx.doi.org/10.1080/02681219580000511.
85. Giles SS, Batinic-Haberle I, Perfect JR, Cox GM. 2005. Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth. Eukaryot Cell 4:46-54. http://dx.doi.org/10.1128/EC.4.1.46-54.2005.
86. Narasipura SD, Ault JG, Behr MJ, Chaturvedi V, Chaturvedi S. 2003. Characterization of Cu,Zn superoxide dismutase (SOD1) gene knockout mutant of Cryptococcus neoformans var. gattii: role in biology and virulence. Mol Microbiol 47:1681-1694.
87. Narasipura SD, Chaturvedi V, Chaturvedi S. 2005. Characterization of Cryptococcus neoformans variety gattii SOD2 reveals distinct roles of the two superoxide dismutases in fungal biology and virulence. Mol Microbiol 55:1782-1800. http://dx.doi.org/10.1111/j.1365-2958.2005.04503.x.
88. Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT. 2006. Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot Cell 5:488-498. http://dx.doi.org/10.1128/EC.5.3.488-498.2006.
89. Cox GM, Harrison TS, McDade HC, Taborda CP, Heinrich G, Casadevall A, Perfect JR. 2003. Superoxide dismutase influences the virulen ce of Cryptococcus neoformans by affecting growth within macro-phages. Infect Immun 71:173-180. http://dx.doi.org/10.1128/IAI.71.1.173-180.2003.
90. Jacobson ES, Jenkins ND, Todd JM. 1994. Relationship between superoxide- dismutase and melanin in a pathogenic fungus. Infect Immun 62:4085-4086.
91. Chen SC, Muller M, Zhou JZ, Wright LC, Sorrell TC. 1997. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 175:414-420. http://dx.doi.org/10.1093/infdis/175.2.414.
92. Chen SCA, Wright LC, Santangelo RT, Muller M, Moran VR, Kuchel PW, Sorrell TC. 1997. Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Infect Immun 65:405-411.
93. Henry J, Guillotte A, Luberto C, Del Poeta M. 2011. Characterization of inositol phospho-sphingolipid-phospholipase C 1 (Isc1) in Cryptococcus neoformans reveals unique biochemical features. FEBS Lett 585:635-640. http://dx.doi.org/10.1016/j.febslet.2011.01.015.
94. Barrett-Bee K, Hayes Y, Wilson RG, Ryley JF. 1985. A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. J Gen Microbiol 131:1217-1221.
95. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, Djordjevic J, Shounan Y, Wright L. 2004. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun 72:2229-2239. http://dx.doi.org/10.1128/IAI.72.4.2229-2239.2004.
96. Chen SC, Wright LC, Golding JC, Sorrell TC. 2000. Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J 347:431-439. http://dx.doi.org/10.1042/bj3470431.
97. Siafakas AR, Sorrell TC, Wright LC, Wilson C, Larsen M, Boadle R, Williamson PR, Djordjevic JT. 2007. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J Biol Chem 282:37508-37514. http://dx.doi.org/10.1074/jbc.M707913200.
98. Wright LC, Santangelo RM, Ganendren R, Payne J, Djordjevic JT, Sorrell TC. 2007. Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids. Eukaryot Cell 6:37-47. http://dx.doi.org/10.1128/EC.00262-06.
99. Noverr MC, Cox GM, Perfect JR, Huffnagle GB. 2003. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun 71:1538-1547. http://dx.doi.org/10.1128/IAI.71.3.1538-1547.2003.
100. Turner KM, Wright LC, Sorrell TC, Djordjevic JT. 2006. N-linked glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring. Biochim Biophys Acta 1760:1569-1579. http://dx.doi.org/10.1016/j.bbagen.2006.07.002.
101. Chayakulkeeree M, Sorrell TC, Siafakas AR, Wilson CF, Pantarat N, Gerik KJ, Boadle R, Djordjevic JT. 2008. Role and mechanism of phosphatidylinositol- specific phospholipase C in survival and virulence of Cryptococcus neoformans. Mol Microbiol 69:809-826. http://dx.doi.org/10.1111/j.1365-2958.2008.06310.x.
102. Lev S, Desmarini D, Li C, Chayakulkeeree M, Traven A, Sorrell TC, Djordjevic JT. 2013. Phospholipase C of Cryptococcus neoformans regulates homeostasis and virulence by providing inositol trisphosphate as a substrate for Arg1 kinase. Infect Immun 81:1245-1255. http://dx.doi.org/10.1128/IAI.01421-12.
103. Bauman AL, Scott JD. 2002. Kinase- and phosphatase-anchoring proteins: harnessing the dynamic duo. Nat Cell Biol 4:E203-E206. http://dx.doi.org/10.1038/ncb0802-e203.
104. McConnell JL, Wadzinski BE. 2009. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 75:1249-1261. http://dx.doi.org/10.1124/mol.108.053140.
105. Collopy-Junior I, Esteves FF, Nimrichter L, Rodrigues ML, Alviano CS, Meyer-Fernandes JR. 2006. An ectophosphatase activity in Cryptococcus neoformans. FEMS Yeast Res 6:1010-1017. http://dx.doi.org/10.1111/j.1567-1364.2006.00105.x.
106. Lev S, Crossett B, Cha SY, Desmarini D, Li C, Chayakulkeeree M, Wilson CF, Williamson PR, Sorrell TC, Djordjevic JT. 2014. Identification of Aph1, a phosphate-regulated, secreted, and vacuolar acid phosphatase in Cryptococcus neoformans. MBio 5:e01649-14. http://dx.doi.org/10.1128/mBio.01649-14.
107. Brueske CH. 1986. Proteolytic activity of a clinical isolate of Cryptococcus neoformans. J Clin Microbiol 23:631-633.
108. Chen LC, Blank ES, Casadevall A. 1996. Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol 3:570-574.
109. Ruma-Haynes P, Brownlee AG, Sorrell TC. 2000. A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 isolates. J Med Microbiol 49:733-737. http://dx.doi.org/10.1099/0022-1317-49-8-733.
110. Il Yoo J, Lee YS, Song CY, Kim BS. 2004. Purification and characterization of a 43-kilodalton extracellular serine proteinase from Cryptococcus neoformans. J Clin Microbiol 42:722-726. http://dx.doi.org/10.1128/JCM.42.2.722-726.2004.
111. Pinti M, Orsi CF, Gibellini L, Esposito R, Cossarizza A, Blasi E, Peppoloni S, Mussini C. 2007. Identification and characterization of an aspartyl protease from Cryptococcus neoformans. FEBS Lett 581:3882-3886. http://dx.doi.org/10.1016/j.febslet.2007.07.006.
112. Chen LC, Pirofski LA, Casadevall A. 1997. Extracellular proteins of Cryptococcus neoformans and host antibody response. Infect Immun 65: 2599-2605.
113. Vu K, Tham R, Uhrig JP, Thompson GR, III, Na Pombejra S, Jamklang M, Bautos JM, Gelli A. 2014. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. MBio 5:e01101-14. http://dx.doi.org/10.1128/mBio.01101-14.
114. Perfect JR, Toffaletti DL, Rude TH. 1993. The gene encoding phosphoribosylaminoimidazole carboxylase (Ade2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid. Infect Immun 61:4446-4451.
115. Garrad RC, Bhattacharjee JK. 1992. Lysine biosynthesis in selected pathogenic fungi—characterization of lysine auxotrophs and the cloned Lys1 gene of Candida albicans. J Bacteriol 174:7379-7384.
116. Lodge JK, Johnson RL, Weinberg RA, Gordon JI. 1994. Comparison of myristoyl-CoA:protein N-myristoyltransferases from three pathogenic fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans. J Biol Chem 269:2996-3009.
117. Lodge JK, Jackson-Machelski E, Toffaletti DL, Perfect JR, Gordon JI. 1994. Targeted gene replacement demonstrates that myristoyl-CoA/protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A 91:12008-12012. http://dx.doi.org/10.1073/pnas.91.25.12008.
118. Langner CA, Lodge JK, Travis SJ, Caldwell JE, Lu TB, Li Q, Bryant ML, Devadas B, Gokel GW, Kobayashi GS, Gordon JI. 1992. 4-Oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. J Biol Chem 267:17159-17169.
119. Lamb DC, Corran A, Baldwin BC, Kwon-Chung J, Kelly SL. 1995. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett 368:326-330. http://dx.doi.org/10.1016/0014-5793(95)00684-2.
120. Bozzette SA, Larsen RA, Chiu J, Leal MAE, Jacobsen J, Rothman P, Robinson P, Gilbert G, Mccutchan JA, Tilles J, Leedom JM, Richman DD. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324:580-584. http://dx.doi.org/10.1056/NEJM199102283240902.
121. Anonymous. 1980. Garlic in cryptococcal meningitis: a preliminary report of 21 cases. Chin Med J (Engl) 93:123-126.
122. Haynes MP, Chong PLG, Buckley HR, Pieringer RA. 1996. Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells. Biochemistry 35:7983-7992. http://dx.doi.org/10.1021/bi952910c.
123. Venkateswarlu K, Taylor M, Manning NJ, Rinaldi MG, Kelly SL. 1997. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 41:748-751.
124. Kelly SL, Lamb DC, Taylor M, Corran AJ, Baldwin BC, Powderly WG. 1994. Resistance to amphotericin B associated with defective sterol delta 8¡7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 122:39-42. http://dx.doi.org/10.1111/j.1574-6968.1994.tb07140.x.
125. Luberto C, Toffaletti DL, Wills EA, Tucker SC, Casadevall A, Perfect JR, Hannun YA, Del Poeta M. 2001. Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev 15:201-212. http://dx.doi.org/10.1101/gad.856001.
126. Shea JM, Kechichian TB, Luberto C, Del Poeta M. 2006. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun 74:5977-5988. http://dx.doi.org/10.1128/IAI.00768-06.
127. Del Poeta M, Nimrichter L, Rodrigues ML, Luberto C. 2014. Synthesis and biological properties of fungal glucosylceramide. PLoS Pathog 10: e1003832. http://dx.doi.org/10.1371/journal.ppat.1003832.
128. Rittershaus PC, Kechichian TB, Allegood JC, Merrill AH, Hennig M, Luberto C, Del Poeta M. 2006. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J Clin Invest 116: 1651-1659. http://dx.doi.org/10.1172/JCI27890.
129. Nosanchuk JD, Ovalle R, Casadevall A. 2001. Glyphosate inhibits melanization of Cryptococcus neoformans and prolongs survival of mice after systemic infection. J Infect Dis 183:1093-1099. http://dx.doi.org/10.1086/319272.
130. De Clercq E. 2013. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv Pharmacol 67:317-358. http://dx.doi.org/10.1016/B978-0-12-405880-4.00009-3.
131. Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palu G. 2014. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 71:3659-3683. http://dx.doi.org/10.1007/s00018-014-1615-2.
132. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180:448-453. http://dx.doi.org/10.1086/314871.
133. Blasi E, Colombari B, Orsi CF, Pinti M, Troiano L, Cossarizza A, Esposito R, Peppoloni S, Mussini C, Neglia R. 2004. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS Immunol Med Microbiol 42:187-195. http://dx.doi.org/10.1016/j.femsim.2004.05.001.
134. Campbell LT, Chen C, Ferdous J, Padula MP, Harry E, Hofer M, Campbell IL, Carter DA. 2015. Cryptococcus strains with different pathogenic potential have diverse protein secretomes. Eukaryot Cell 14: 554-563. http://dx.doi.org/10.1128/EC.00052-15.
135. Maligie MA, Selitrennikoff CP. 2005. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 49:2851-2856. http://dx.doi.org/10.1128/AAC.49.7.2851-2856.2005.
136. Casal M, Linares MJ. 1983. Contribution to the study of the enzymatic profiles of yeast organisms with medical interest. Mycopathologia 81: 155-159. http://dx.doi.org/10.1007/BF00436820.
137. Mason DL, Wilson CL. 1979. Cytochemical and biochemical identification of lysosomes in Cryptococcus neoformans. Mycopathologia 68: 183-190. http://dx.doi.org/10.1007/BF00578528.
138. Janbon G, Himmelreich U, Moyrand F, Improvisi L, Dromer F. 2001. Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol 42:453-467. http://dx.doi.org/10.1046/j.1365-2958.2001.02651.x.
139. Baker LG, Specht CA, Donlin MJ, Lodge JK. 2007. Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryot Cell 6:855-867. http://dx.doi.org/10.1128/EC.00399-06.
140. Banks IR, Specht CA, Donlin MJ, Gerik KJ, Levitz SM, Lodge JK. 2005. A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans. Eukaryot Cell 4:1902-1912. http://dx.doi.org/10.1128/EC.4.11.1902-1912.2005.
141. Baker LG, Specht CA, Lodge JK. 2009. Chitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans. Eukaryot Cell 8:1692-1705. http://dx.doi.org/10.1128/EC.00227-09.
142. Polacheck I, Kwon-Chung KJ. 1980. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol 142:15-20.
143. Wills EA, Roberts IS, Del Poeta M, Rivera J, Casadevall A, Cox GM, Perfect JR. 2001. Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol 40:610-620. http://dx.doi.org/10.1046/j.1365-2958.2001.02401.x.
144. Cottrell TR, Griffith CL, Liu H, Nenninger AA, Doering TL. 2007. The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis. Eukaryot Cell 6:776-785. http://dx.doi.org/10.1128/EC.00015-07.
145. Biondo C, Beninati C, Bombaci M, Messina L, Mancuso G, Midiri A, Galbo R, Teti G. 2003. Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans. Infect Immun 71:5412-5417. http://dx.doi.org/10.1128/IAI.71.9.5412-5417.2003.
146. Erickson T, Liu L, Gueyikian A, Zhu XD, Gibbons J, Williamson PR. 2001. Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol Microbiol 42:1121-1131. http://dx.doi.org/10.1046/j.1365-2958.2001.02712.x.
147. Bar-Peled M, Griffith CL, Doering TL. 2001. Functional cloning and characterization of a UDP-glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis. Proc Natl Acad Sci U S A 98:12003-12008. http://dx.doi.org/10.1073/pnas.211229198.
148. Levitz SM, Specht CA. 2006. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res 6:513-524. http://dx.doi.org/10.1111/j.1567-1364.2006.00071.x.
149. White CW, Jacobson ES. 1993. Mannosyl transfer in Cryptococcus neoformans. Can J Microbiol 39:129-133. http://dx.doi.org/10.1139/m93-019.
150. Fiskin AM, Zalles MC, Garrison RG. 1990. Electron cytochemical studies of Cryptococcus neoformans grown on uric acid and related sources of nitrogen. J Med Vet Mycol 28:197-207. http://dx.doi.org/10.1080/02681219080000261.
151. Biondo C, Mancuso G, Midiri A, Bombaci M, Messina L, Beninati C, Teti G. 2006. Identification of major proteins secreted by Cryptococcus neoformans. FEMS Yeast Res 6:645-651. http://dx.doi.org/10.1111/j.1567-1364.2006.00043.x.
152. Eigenheer RA, Jin Lee Y, Blumwald E, Phinney BS, Gelli A. 2007. Extracellular glycosylphosphatidylinositol-anchored mannoproteins and proteases of Cryptococcus neoformans. FEMS Yeast Res 7:499-510. http://dx.doi.org/10.1111/j.1567-1364.2006.00198.x.
153. Bien CM, Chang YC, Nes WD, Kwon-Chung KJ, Espenshade PJ. 2009. Cryptococcus neoformans site-2 protease is required for virulence and survival in the presence of azole drugs. Mol Microbiol 74:672-690. http://dx.doi.org/10.1111/j.1365-2958.2009.06895.x.
154. Miyakoshi S, Uchiyama H, Someya T, Satoh T, Tabuchi T. 1987. Distribution of the methylcitric acid cycle and beta-oxidation pathway for propionate catabolism in fungi. Agric Biol Chem 51:2381-2387. http://dx.doi.org/10.1271/bbb1961.51.2381.
155. Vanden Bossche H, Marichal P, Le Jeune L, Coene MC, Gorrens J, Cools W. 1993. Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 37:2101-2105. http://dx.doi.org/10.1128/AAC.37.10.2101.
156. Niehaus WG, Richardson SB, Wolz RL. 1996. Slow-binding inhibition of 6-phosphogluconate dehydrogenase by zinc ion. Arch Biochem Biophys 333:333-337. http://dx.doi.org/10.1006/abbi.1996.0399.
157. Niehaus WG, White RH, Richardson SB, Bourne A, Ray WK. 1995. Polyethylene sulfonate: a tight-binding inhibitor of 6-phosphogluconate dehydrogenase of Cryptococcus neoformans. Arch Biochem Biophys 324: 325-330. http://dx.doi.org/10.1006/abbi.1995.0045.
158. Thaker TM, Tanabe M, Fowler ML, Preininger AM, Ingram-Smith C, Smith KS, Iverson TM. 2013. Crystal structures of acetate kinases from the eukaryotic pathogens Entamoeba histolytica and Cryptococcus neoformans. J Struct Biol 181:185-189. http://dx.doi.org/10.1016/j.jsb.2012.11.001.
159. Missall TA, Pusateri ME, Donlin MJ, Chambers KT, Corbett JA, Lodge JK. 2006. Posttranslational, translational, and transcriptional responses to nitric oxide stress in Cryptococcus neoformans: implications for virulence. Eukaryot Cell 5:518-529. http://dx.doi.org/10.1128/EC.5.3.518-529.2006.
160. Alspaugh JA, Pukkila-Worley R, Harashima T, Cavallo LM, Funnell D, Cox GM, Perfect JR, Kronstad JW, Heitman J. 2002. Adenylyl cyclase functions downstream of the G alpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell 1:75-84. http://dx.doi.org/10.1128/EC.1.1.75-84.2002.
161. Akhter S, McDade HC, Gorlach JM, Heinrich G, Cox GM, Perfect JR. 2003. Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans. Infect Immun 71:5794-5802. http://dx.doi.org/10.1128/IAI.71.10.5794-5802.2003.
162. Bahn YS, Cox GM, Perfect JR, Heitman J. 2005. Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol 15:2013-2020. http://dx.doi.org/10.1016/j.cub.2005.09.047.
163. Mogensen EG, Janbon G, Chaloupka J, Steegborn C, Fu MS, Moyrand F, Klengel T, Pearson DS, Geeves MA, Buck J, Levin LR, Muhlschlegel FA. 2006. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryot Cell 5:103-111. http://dx.doi.org/10.1128/EC.5.1.103-111.2006.
164. Wang YN, Liu TB, Patel S, Jiang LH, Xue CY. 2011. The casein kinase I protein Cck1 regulates multiple signaling pathways and is essential for cell integrity and fungal virulence in Cryptococcus neoformans. Eukaryot Cell 10:1455-1464. http://dx.doi.org/10.1128/EC.05207-11.
165. Giles SS, Perfect JR, Cox GM. 2005. Cytochrome c peroxidase contributes to the antioxidant defense of Cryptococcus neoformans. Fungal Genet Biol 42:20-29. http://dx.doi.org/10.1016/j.fgb.2004.09.003.
166. Biondo C, Beninati C, Delfino D, Oggioni M, Mancuso G, Midiri A, Bombaci M, Tomaselli G, Teti G. 2002. Identification and cloning of a cryptococcal deacetylase that produces protective immune responses. Infect Immun 70:2383-2391. http://dx.doi.org/10.1128/IAI.70.5.2383-2391.2002.
167. Kelleher DJ, Banerjee S, Cura AJ, Samuelson J, Gilmore R. 2007. Dolichol-linked oligosaccharide selection by the oligosaccharyltransferase in protist and fungal organisms. J Cell Biol 177:29-37. http://dx.doi.org/10.1083/jcb.200611079.
168. Idnurm A, Heitman J. 2010. Ferrochelatase is a conserved downstream target of the blue light-sensing white collar complex in fungi. Microbiology 156:2393-2407. http://dx.doi.org/10.1099/mic.0.039222-0.
169. Hu GG, Kronstad JW. 2010. A putative P-type ATPase, Apt1, is involved in stress tolerance and virulence in Cryptococcus neoformans. Eukaryot Cell 9:74-83. http://dx.doi.org/10.1128/EC.00289-09.
170. Rizzo J, Oliveira DL, Joffe LS, Hu G, Gazos-Lopes F, Fonseca FL, Almeida IC, Frases S, Kronstad JW, Rodrigues ML. 2014. Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans. Eukaryot Cell 13:715-726. http://dx.doi.org/10.1128/EC.00273-13.
171. Niehaus WG, Mallett TC. 1994. Purification and characterization of glucose-6-phosphate dehydrogenase from Cryptococcus neoformans identification as “nothing dehydrogenase.” Arch Biochem Biophys 313: 304-309.
172. Safrin RE, Lancaster LA, Davis CE, Braude AI. 1986. Differentiation of Cryptococcus neoformans serotypes by isoenzyme electrophoresis. Am J Clin Pathol 86:204-208.
173. Missall TA, Cherry-Harris JF, Lodge JK. 2005. Two glutathione peroxidases in the fungal pathogen Cryptococcus neoformans are expressed in the presence of specific substrates. Microbiology 151:2573-2581. http://dx.doi.org/10.1099/mic.0.28132-0.
174. Kingsbury JM, McCusker JH. 2008. Threonine biosynthetic genes are essential in Cryptococcus neoformans. Microbiology 154:2767-2775. http://dx.doi.org/10.1099/mic.0.2008/019729-0.
175. Nazi I, Scott A, Sham A, Rossi L, Williamson PR, Kronstad JW, Wright GD. 2007. Role of homoserine transacetylase as a new target for antifungal agents. Antimicrob Agents Chemother 51:1731-1736. http://dx.doi.org/10.1128/AAC.01400-06.
176. Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, Chang YC, LaMunyon CW, Plaas A, Huang SH. 2007. Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell 6:1486-1496. http://dx.doi.org/10.1128/EC.00120-07.
177. Parker AR, Moore TD, Edman JC, Schwab JM, Davisson VJ. 1994. Cloning, sequence analysis and expression of the gene encoding imidazole glycerol phosphate dehydratase in Cryptococcus neoformans. Gene 145:135-138. http://dx.doi.org/10.1016/0378-1119(94)90336-0.
178. Morrow CA, Stamp A, Valkov E, Kobe B, Fraser JA. 2010. Crystallization and preliminary X-ray analysis of mycophenolic acidresistant and mycophenolic acid-sensitive forms of IMP dehydrogenase from the human fungal pathogen Cryptococcus. Acta Crystallogr Sect F Struct Biol Cryst Commun 66:1104-1107. http://dx.doi.org/10.1107/S1744309110031659.
179. Heung LJ, Luberto C, Plowden A, Hannun YA, Del Poeta M. 2004. The sphingolipid pathway regulates Pkc1 through the formation of diacylglycerol in Cryptococcus neoformans. J Biol Chem 279:21144-21153. http://dx.doi.org/10.1074/jbc.M312995200.
180. Cheon SA, Jung KW, Chen YL, Heitman J, Bahn YS, Kang HA. 2011. Unique evolution of the UPR pathway with a novel bZIP transcription factor, Hxl1, for controlling pathogenicity of Cryptococcus neoformans. PLoS Pathog 7:e1002177. http://dx.doi.org/10.1371/journal.ppat.1002177.
181. Rude TH, Toffaletti DL, Cox GM, Perfect JR. 2002. Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect Immun 70:5684-5694. http://dx.doi.org/10.1128/IAI.70.10.5684-5694.2002.
182. Mahmoud YA, el Souod SM, Niehaus WG. 1995. Purification and characterization of malate dehydrogenase from Cryptococcus neoformans. Arch Biochem Biophys 322:69-75. http://dx.doi.org/10.1006/abbi.1995.1437.
183. Perfect JR, Rude TH, Wong B, Flynn T, Chaturvedi V, Niehaus W. 1996. Identification of a Cryptococcus neoformans gene that directs expression of the cryptic Saccharomyces cerevisiae mannitol dehydrogenase gene. J Bacteriol 178:5257-5262.
184. Suvarna K, Bartiss A, Wong B. 2000. Mannitol-1-phosphate dehydrogenase from Cryptococcus neoformans is a zinc-containing long-chain alcohol/polyol dehydrogenase. Microbiology 146:2705-2713. http://dx.doi.org/10.1099/00221287-146-10-2705.
185. Olson GM, Fox DS, Wang P, Alspaugh JA, Buchanan KL. 2007. Role of protein O-mannosyltransferase Pmt4 in the morphogenesis and virulence of Cryptococcus neoformans. Eukaryot Cell 6:222-234. http://dx.doi.org/10.1128/EC.00182-06.
186. Hicks JK, Bahn YS, Heitman J. 2005. Pde1 phosphodiesterase modulates cyclic AMP levels through a protein kinase A-mediated negative feedback loop in Cryptococcus neoformans. Eukaryot Cell 4:1971-1981. http://dx.doi.org/10.1128/EC.4.12.1971-1981.2005.
187. Hast MA, Nichols CB, Armstrong SM, Kelly SM, Hellinga HW, Alspaugh JA, Beese LS. 2011. Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J Biol Chem 286:35149-35162. http://dx.doi.org/10.1074/jbc.M111.250506.
188. Gerik KJ, Donlin MJ, Soto CE, Banks AM, Banks IR, Maligie MA, Selitrennikoff CP, Lodge JK. 2005. Cell wall integrity is dependent on the PKC1 signal transduction pathway in Cryptococcus neoformans. Mol Microbiol 58:393-408. http://dx.doi.org/10.1111/j.1365-2958.2005.04843.x.
189. Jin LH, Kryukov K, Suzuki Y, Imanishi T, Ikeo K, Gojobori T. 2009. The evolutionary study of small RNA-directed gene silencing pathways by investigating RNase III enzymes. Gene 435:1-8. http://dx.doi.org/10.1016/j.gene.2008.12.022.
190. Kingsbury JM, Yang Z, Ganous TM, Cox GM, McCusker JH. 2004. Novel chimeric spermidine synthase-saccharopine dehydrogenase gene (SPE3-LYS9) in the human pathogen Cryptococcus neoformans. Eukaryot Cell 3:752-763. http://dx.doi.org/10.1128/EC.3.3.752-763.2004.
191. Ternes P, Sperling P, Albrecht S, Franke S, Cregg JM, Warnecke D, Heinz E. 2006. Identification of fungal sphingolipid C9- methyltransferases by phylogenetic profiling. J Biol Chem 281:5582-5592.
192. Zhu J, Lu J, Zhou Y, Li Y, Cheng J, Zheng C. 2006. Design, synthesis, and antifungal activities in vitro of novel tetrahydroisoquinoline compounds based on the structure of lanosterol 14alpha-demethylase (CYP51) of fungi. Bioorg Med Chem Lett 16:5285-5289. http://dx.doi.org/10.1016/j.bmcl.2006.08.001.
193. Nes WD, Zhou W, Ganapathy K, Liu J, Vatsyayan R, Chamala S, Hernandez K, Miranda M. 2009. Sterol 24-C-methyltransferase: an enzymatic target for the disruption of ergosterol biosynthesis and homeostasis in Cryptococcus neoformans. Arch Biochem Biophys 481:210-218. http://dx.doi.org/10.1016/j.abb.2008.11.003.
194. Missall TA, Pusateri ME, Lodge JK. 2004. Thiol peroxidase is critical for virulence and resistance to nitric oxide and peroxide in the fungal pathogen, Cryptococcus neoformans. Mol Microbiol 51:1447-1458. http://dx.doi.org/10.1111/j.1365-2958.2004.03921.x.
195. Missall TA, Lodge JK. 2005. Thioredoxin reductase is essential for viability in the fungal pathogen Cryptococcus neoformans. Eukaryot Cell 4:487-489. http://dx.doi.org/10.1128/EC.4.2.487-489.2005.
196. Livi LL, Edman U, Schneider GP, Greene PJ, Santi DV. 1994. Cloning, expression and characterization of thymidylate synthase from Cryptococcus neoformans. Gene 150:221-226. http://dx.doi.org/10.1016/0378-1119(94)90430-8.
197. Petzold EW, Himmelreich U, Mylonakis E, Rude T, Toffaletti D, Cox GM, Miller JL, Perfect JR. 2006. Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun 74:5877-5887. http://dx.doi.org/10.1128/IAI.00624-06.
198. Beverley SM, Owens KL, Showalter M, Griffith CL, Doering TL, Jones VC, McNeil MR. 2005. Eukaryotic UDP-galactopyranose mutase (GLF gene) in microbial and metazoal pathogens. Eukaryot Cell 4:1147-1154. http://dx.doi.org/10.1128/EC.4.6.1147-1154.2005.
199. Jacobson ES. 1987. Cryptococcal UDP-glucose dehydrogenase: enzymic control of capsular biosynthesis. J Med Vet Mycol 25:131-135. http://dx.doi.org/10.1080/02681218780000201.
200. Reilly MC, Levery SB, Castle SA, Klutts JS, Doering TL. 2009. A novel xylosylphosphotransferase activity discovered in Cryptococcus neoformans. J Biol Chem 284:36118-36127. http://dx.doi.org/10.1074/jbc.M109.056226.
201. Block ER, Jennings AE, Bennett JE. 1973. 5-Fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 3:649-656. http://dx.doi.org/10.1128/AAC.3.6.649.
202. Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. 2007. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 51:383-385. http://dx.doi.org/10.1128/AAC.00446-06.